Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>PYC is a clinical-stage biotechnology company focused on developing a new generation of RNA therapeutics for rare genetic diseases with no or limited treatment options.</li>
  <li>The company's key competitive advantage is its proprietary drug delivery platform, which utilizes Cell-Penetrating Peptides (CPPs) to overcome the challenge of delivering RNA drugs into target cells, potentially increasing efficacy and safety.</li>
  <li>With three drug candidates in human clinical trials for ocular and kidney diseases, and a fourth expected to enter trials in 2027, PYC is approaching key clinical readouts that represent major potential value inflection points and inherent binary risks.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  PYC is a clinical-stage biotechnology company focused on developing a new generation of RNA therapeutics for rare genetic diseases with no or limited treatment options.
  The company's key competitive advantage is its proprietary drug delivery platform, which utilizes Cell-Penetrating Peptides (CPPs) to overcome the challenge of delivering RNA drugs into target cells, potentially increasing efficacy and safety.
  With three drug candidates in human clinical trials for ocular and kidney diseases, and a fourth expected to enter trials in 2027, PYC is approaching key clinical readouts that represent major potential value inflection points and inherent binary risks.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: PYC Therapeutics (PYC AU) - Aug 2026

Index Rebal/Special Situations, Quiddity Advisors

Janaghan Jeyakumar, CFA

Index Rebal/Special Situations

Quiddity Advisors

Pan-Asia Catalysts/Events

Index Rebalance

<ul>
<li>In this insight, we present our expectations for ASX 200, 100, 50, and 20 for the December 2026 index rebal event.</li>
<li>We expect one change for ASX 100 and six changes for ASX 200. We do not see any changes for ASX 20 and ASX 50.</li>
<li>There could also be intra-review index changes over the next few months. By our current measure, those will be quite big in dollar terms and ADV impact.</li>
</ul>


In this insight, we present our expectations for ASX 200, 100, 50, and 20 for the December 2026 index rebal event.
We expect one change for ASX 100 and six changes for ASX 200. We do not see any changes for ASX 20 and ASX 50.
There could also be intra-review index changes over the next few months. By our current measure, those will be quite big in dollar terms and ADV impact.


Quiddity Leaderboard ASX Dec26: Multiple Changes During the Rebal + Some Intra-Review Changes

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

Shenton Research

Shenton Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Sep 18th (reported today). The aggregated short interest was USD49.8bn.</li>
<li>We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in Codan, Sunrise Energy Metals, TPG Telecom, Qbe Insurance, EQ Resources.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Sep 18th (reported today). The aggregated short interest was USD49.8bn.
We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in Codan, Sunrise Energy Metals, TPG Telecom, Qbe Insurance, EQ Resources.


ASX Short Interest Weekly (Sep 18th): Codan, Sunrise Energy Metals, TPG Telecom, Qbe Insurance

Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

<ul>
<li>Multiple index families rebalance at the close today, driving huge flows across Australian stocks. Estimates indicate over A$5bn to trade from passive trackers.</li>
<li>Among index adds, we see large flows in <a href="https://www.smartkarma.com/entities/eq-resources-limited" target="_blank" data-smartkarma-citation="entities:14984:1" rel="noopener">EQ Resources (EQR AU)</a>, <a href="https://www.smartkarma.com/entities/codan-ltd-australia" target="_blank" data-smartkarma-citation="entities:6189:1" rel="noopener">Codan (CDA AU)</a>, <a href="https://www.smartkarma.com/entities/sunrise-energy-metals-ltd" target="_blank" data-smartkarma-citation="entities:11810:1" rel="noopener">Sunrise Energy Metals (SRL AU)</a> and <a href="https://www.smartkarma.com/entities/core-lithium-ltd" target="_blank" data-smartkarma-citation="entities:14712:1" rel="noopener">Core Lithium Ltd (CXO AU)</a>. </li>
<li>Among index deletes, the largest flows are in <a href="https://www.smartkarma.com/entities/evolution-mining-ltd" target="_blank" data-smartkarma-citation="entities:18363:1" rel="noopener">Evolution Mining (EVN AU)</a>, <a href="https://www.smartkarma.com/entities/atlas-arteria-ltd" target="_blank" data-smartkarma-citation="entities:14430:1" rel="noopener">Atlas Arteria (ALX AU)</a>, <a href="https://www.smartkarma.com/entities/cochlear-ltd" target="_blank" data-smartkarma-citation="entities:918:1" rel="noopener">Cochlear (COH AU)</a>, <a href="https://www.smartkarma.com/entities/graincorp-ltd" target="_blank" data-smartkarma-citation="entities:18531:1" rel="noopener">Graincorp (GNC AU)</a> and <a href="https://www.smartkarma.com/entities/amalgamated-holdings-ltd" target="_blank" data-smartkarma-citation="entities:20978:1" rel="noopener">Event Hospitality and Entertainment (EVT AU)</a>. </li>
</ul>


Multiple index families rebalance at the close today, driving huge flows across Australian stocks. Estimates indicate over A$5bn to trade from passive trackers.
Among index adds, we see large flows in EQ Resources (EQR AU), Codan (CDA AU), Sunrise Energy Metals (SRL AU) and Core Lithium Ltd (CXO AU). 
Among index deletes, the largest flows are in Evolution Mining (EVN AU), Atlas Arteria (ALX AU), Cochlear (COH AU), Graincorp (GNC AU) and Event Hospitality and Entertainment (EVT AU). 


Australia: A$5bn+ to Trade at the Close Today Across Local & Global Indices

Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>In last month’s monetary policy decision, the Reserve Bank of Australia (RBA) kept interest rate unchanged at 4.35%.</li>
<li>According to a Reuters poll, a majority of the economists predicted interest rates to remain unchanged in the current quarter, followed by a 25bps cut to 4.10% in 4Q24.</li>
<li>Amid possible rate cut talks both in the domestic as well as the U.S. market, we want to take a look at Australian biotech companies.</li>
</ul>


In last month’s monetary policy decision, the Reserve Bank of Australia (RBA) kept interest rate unchanged at 4.35%.
According to a Reuters poll, a majority of the economists predicted interest rates to remain unchanged in the current quarter, followed by a 25bps cut to 4.10% in 4Q24.
Amid possible rate cut talks both in the domestic as well as the U.S. market, we want to take a look at Australian biotech companies.


Australian Biotech Companies Amid Talk of Likely Interest Rate Cut

Australia

Pyc Therapeutics Limited operates as a pharmaceutical company. The Company develops drugs and medicine for various types of diseases. Pyc Therapeutics serves customers in Australia.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

PYC Therapeutics (PYC AU)

Primer: PYC Therapeutics (PYC AU) - Aug 2026

PYC is a clinical-stage biotechnology company focused on developing a new generation of RNA therapeutics for rare genetic diseases with no or...

αSK Primers

Quiddity Leaderboard ASX Dec26: Multiple Changes During the Rebal + Some Intra-Review Changes

Although we currently see zero changes for ASX 50, there are multiple potential DELs close to the deletion border. If they underperform other...

Janaghan Jeyakumar, CFA

ASX Short Interest Weekly (Sep 18th): Codan, Sunrise Energy Metals, TPG Telecom, Qbe Insurance

We analyzed ASX short interest report for the past week and highlight short interest changes in Codan, Sunrise Energy Metals, TPG Telecom, Qbe...

Ke Yan, CFA, FRM

Australia: A$5bn+ to Trade at the Close Today Across Local & Global Indices

Multiple index families rebalance in Oz at the close today. Estimated passive trading is A$5bn+. Shorts have built up in a lot of stocks and there...

Brian Freitas

Australian Biotech Companies Amid Talk of Likely Interest Rate Cut

RBA keeps interest rates steady at 4.35%, while economists predict possible cut to 4.10% in 4Q24. Australian biotech companies should be in focus...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Primer: PYC Therapeutics (PYC AU) - Aug 2026

PYC is a clinical-stage biotechnology company focused on developing a new generation of RNA therapeutics for rare genetic diseases with no or...

αSK Primers

Quiddity Leaderboard ASX Dec26: Multiple Changes During the Rebal + Some Intra-Review Changes

Although we currently see zero changes for ASX 50, there are multiple potential DELs close to the deletion border. If they underperform other...

Janaghan Jeyakumar, CFA

ASX Short Interest Weekly (Sep 18th): Codan, Sunrise Energy Metals, TPG Telecom, Qbe Insurance

We analyzed ASX short interest report for the past week and highlight short interest changes in Codan, Sunrise Energy Metals, TPG Telecom, Qbe...

Ke Yan, CFA, FRM

Australia: A$5bn+ to Trade at the Close Today Across Local & Global Indices

Multiple index families rebalance in Oz at the close today. Estimated passive trading is A$5bn+. Shorts have built up in a lot of stocks and there...

Brian Freitas

Australian Biotech Companies Amid Talk of Likely Interest Rate Cut

​RBA keeps interest rates steady at 4.35%, while economists predict possible cut to 4.10% in 4Q24. Australian biotech companies should be in focus...

Tina Banerjee

RBA keeps interest rates steady at 4.35%, while economists predict possible cut to 4.10% in 4Q24. Australian biotech companies should be in focus...